Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Combining BCL-2 and MCL-1 inhibitors in AML

Andrew Wei • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Venetoclax

Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses the latest research from his institute in the area of targeting apoptosis for the treatment of acute myeloid leukemia (AML). Dr Wei highlights the combinantion of BCL-2 and MCL-1 inhibitors, which have shown potent activity in pre-clinical models and are now moving into trials. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals